Another @wikidoc meeting where the dissemination of medical knowledge and global collaboration come together to build a true academic community. Honored to be part of a project founded by my mentor Dr. @CMichaelGibson that continues to impact medical education worldwide #MedEd
New insights from @CMichaelGibson: NEJM reviews pulmonary embolism treatments, newest data from multivessel PCI in AMI, and more! https://t.co/lBsZhP5mDK
Compared to DAPT using ticagrelor + aspirin, ticagrelor monotherapy beginning 1 month after PCI in pts with ACS undergoing PCI reduces clinically-relevant and major bleeding. Dr. @greggwstone and I discuss results of ULTIMATE-DAPT trial
Selective aldose reductase inhibition with AT-001 no different than placebo in improving peak VO2 in diabetic cardiomyopathy. Dr. Januzzi and I discuss the results of the ARISE-HF study.
BREAKING
Substantial amounts of high quality randomized clinical trial data demonstrate improved heart outcomes with intermittent fasting.
One of the world's experts in the area, Dr. Pam Taub, discusses the substantial shortcomings of observational nutritional data that the media are reporting on that are not consistent with previous high quality data.
Be skeptical of the study that the mainstream media is reporting on. Support studies that truly test the question.
Mixing or matching mRNA #COVID19 booster provides similar outcomes in a network meta analysis
“a heterologous or a homologous third dose booster can confer an equal level of protection” https://t.co/xn1EdajMcx
The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’
We must move beyond viewing obesity as a moral failing and the goal of being thin “vanity”
Obesity is a complex disease & treating it improves health outcomes https://t.co/ajKxIM0yFd
What defines a successful PCI outcome? Watch @CMichaelGibson and other experts discuss the challenges of #MVO post-PCI for #STEMI and how #SSO2 Therapy can have an impact. https://t.co/JseKn0sXWc
It‘s not too late for #sciencesunday 🔬🧬
Targeting cholesterol efflux after myocardial infarction could help to stabilize vulnerable plaques 🫀
👉 Review by @CMichaelGibson and colleagues, published in @JAHA_AHA
👉 Phase 3 clinical study, using human APO-I CSL112 on the way
20% of the population may have a genetic abnormality in Lp(a) which is not treatable with statins or exercise
Giving an RNA silencing molecule #siRNASLN360 was well tolerated, & reduced Lp(a) in a dose dependent fashion (10% up to 98%).
https://t.co/XlrYPnBdrE
Digital technologies and the democratization of clinical research: Social media, wearables, and artificial intelligence
by Baim CEO @CMichaelGibson, and Baim faculty @skorjianmd
https://t.co/WLQkjPsNLR